Atorvastatin: A Potential Treatment in COVID-19? Atorvastatin: A Potential Treatment in COVID-19?

Results of a randomized trial show no effect for severe COVID-19 patients in ICU, but there was a hint of benefit in the subgroup treated within 7 days of symptom onset in the INSPIRATION-S study.Medscape Medical News
Source: Medscape FamilyMedicine Headlines - Category: Primary Care Tags: Cardiology News Source Type: news

Related Links:

Atherosclerosis progresses undetected and is known as the silent killer. Bu...Read more on AuntMinnie.comRelated Reading: How has the COVID-19 pandemic affected CT CAC testing? CT shines when it comes to COVID-19 risk stratification CT CAC helps determine which patients benefit from statin therapy JAMA Internal Medicine stirs debate on coronary CT AI predicts cardiovascular risk on LDCT lung cancer screening
Source: Headlines - Category: Radiology Source Type: news
Acute respiratory distress syndrome is a heterogenous syndrome with many etiologies for which there are no definitive pharmacologic treatments, despite decades of research. We explore some adjunctive pharmacologic therapies, including neuromuscular blockade, corticosteroids, and inhaled pulmonary vasodilators. Additionally, we explore some investigative therapies, including Vitamin C, beta-agonists, statins, mesenchymal stromal cells, and granulocyte –macrophage colony stimulating factor. We do discuss the potential role of steroids in acute respiratory distress syndrome with severe acute respiratory syndrome coronav...
Source: Critical Care Clinics - Category: Intensive Care Authors: Source Type: research
Discussion None of the tested medications was significantly associated with the COVID-19-duration and -severity up to the end of post-diagnosing week 3. However, there were a few biologically plausible and promising relationships with antidepressants, anticoagulants, and RAAS-inhibitors before p-value adjustment. These should encourage larger and prospective studies to re-evaluate the influence of somatic and psychiatric routine medications on COVID-19-related health outcomes. [...] Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, GermanyArticle in Thieme eJournals: Table o...
Source: Pharmacopsychiatry - Category: Psychiatry Authors: Tags: Original Paper Source Type: research
ConclusionsStatin use in patients hospitalized with COVID-19 was associated with a reduced in-hospital mortality. The protective effect of statin was greater in those with coronary artery disease. These data support continued use of statin therapy in hospitalized patients with COVID-19. Clinical trials are needed to prospectively determine if statin use is effective in lowering the mortality in COVID-19 and other viral infections.
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research
CONCLUSIONS: In this large cohort of hospitalized COVID-19 patients, statins were not independently associated with all-cause mortality during follow-up. Clinically relevant statin-associated adverse effects should be carefully monitored during hospital admission.PMID:34511251 | DOI:10.1016/j.medcli.2021.07.003
Source: Medicina Clinica - Category: General Medicine Authors: Source Type: research
In this study, mature DCs (mDCs), generated from the GM-CSF and IL-4 induced bone marrow cells, were intravenously injected into wild-type mice. Three days later, assays showed that the mDCs were indeed able to return to the thymus. Homing DCs have been mainly reported to deplete thymocytes and induce tolerance. However, medullary TECs (mTECs) play a crucial role in inducing immune tolerance. Thus, we evaluated whether the mDCs homing into the thymus led to TECs depletion. We cocultured mDCs with mTEC1 cells and found that the mDCs induced the apoptosis and inhibited the proliferation of mTEC1 cells. These effects were onl...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
CONCLUSIONS: Small clinical studies reported that general statin use, and specifically, atorvastatin use, are associated with protective effects against COVID-19. Our study corroborrates these findings and supports the investigation of atorvastatin in larger clinical studies. Ultimately, our framework demonstrates one promising way to fast-track the identification of compounds for COVID-19, which could similarly be applied when tackling future pandemics.PMID:34503440 | DOI:10.1186/s10020-021-00356-6
Source: Molecular Medicine - Category: Molecular Biology Authors: Source Type: research
Coronavirus disease 2019 (COVID-19) pandemic is caused by the novel coronavirus that has spread rapidly around the world, leading to high mortality because of multiple organ dysfunction; however, its underlying molecular mechanism is unknown. To determine the molecular mechanism of multiple organ dysfunction, a bioinformatics analysis method based on a time-order gene co-expression network (TO-GCN) was performed. First, gene expression profiles were downloaded from the gene expression omnibus database (GSE161200), and a TO-GCN was constructed using the breadth-first search (BFS) algorithm to infer the pattern of changes in...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Conclusions: Our study showed that the reduction in physical activity during lockdown led to an increase in LDL levels, and therefore, in the risk of ischemic heart disease in dyslipidemic patients with high cardiovascular risk.
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Article Source Type: research
ConclusionsThe study suggested sex differences in the risk of death from COVID-19 with the use of ACEI and ARB among middle-aged and older adults. Sex differences in the risk of hospitalization for COVID-19 with the use of CCB was observed as well. It is of clinical importance that clinicians adopt different CVD treatment approaches for female and male patients with COVID-19.
Source: Drugs and Aging - Category: Geriatrics Source Type: research
More News: Atorvastatin Calcium | Cardiology | COVID-19 | Heart | Lipitor | Primary Care | Statin Therapy | Study | Zivast